Medical innovation does not always begin with a new active substance. Sometimes, it lies in finding a better way to deliver a medication we already know.
Two recent examples are pregabalin retard for neuropathic pain and IPX203, a prolonged-release formulation of carbidopa and levodopa for Parkinson’s disease.
Neuropathic pain may feel burning, electric, stabbing or unusually sensitive to touch. It often becomes particularly disruptive at night, affecting both sleep and daytime functioning.
Pregabalin retard is taken once daily after a full evening meal. Its gastroretentive formulation allows the tablet to remain in the stomach longer and release the active substance gradually over approximately 24 hours.
The aim is not necessarily a stronger effect, but a steadier one: more consistent pain control, simpler dosing and potentially fewer problems with daytime sleepiness or impaired concentration in appropriately selected patients.
Levodopa remains the most effective medication for the motor symptoms of Parkinson’s disease. Because its effect can become shorter and less predictable over time, some patients develop increasingly frequent transitions between good mobility, known as ON time, and periods in which symptoms return, known as OFF time.
IPX203 combines an immediately released component with prolonged-release carbidopa–levodopa in one capsule. Special extended-release pellets are designed to remain longer near the upper small intestine, where levodopa is absorbed.
This may prolong symptom control between doses and reduce the number of daily levodopa administrations for some patients.
Neither formulation is automatically better for everyone. Dose, timing, meals, tolerability and the individual pattern of symptoms remain essential.
Sometimes progress means a new drug.
Sometimes it means allowing an established one to work in a more thoughtful way.
Ask your doctor whether one of these formulations could help improve your quality of life.
https://www.coliquio.de/content/neurologie/ipx203-praxiserfahrung-usa-54983?src=0_nl_sm_0&uac=113573AZ&sso=true
https://www.coliquio.de/content/neurologie/pregabalin-schmerzfrei-durch-nacht-55043?src=0_nl_sm_0&uac=113573AZ&sso=true
Every day, thousands of scientific papers are published around the world—each one offering new insights, clinical refinements, or unexpected discoveries. In a field as delicate and impactful as neurosurgery, staying informed is not only a professional duty but also a promise to those who entrust us with their health.
At J’Arcadia’N, I remain committed to critically reviewing new findings and sharing selected updates that may benefit my patients. This section will offer you:
For example, recent data suggest that early high-dose vitamin D supplementation may reduce disease activity in multiple sclerosis (MS). This emerging evidence comes from both controlled trials and independent reviews:
🔗 High-Dose vitamin D Curbs Disease Activity in Early MS—Medscape Neurology
Such studies remind us that even modest interventions—like correcting vitamin D levels—can have significant outcomes when guided by evidence. Please note, however, that unsupervised self-administration of high-dose vitamin D can lead to vitamin D toxicity. I therefore strongly advise consultation with your physician and appropriate laboratory evaluation of your vitamin D levels before supplementation.
🔗 Further reading: Vitamin D Poisoning—Medscape (German)
And sometimes, a small document can make a large difference:
If you or a loved one lives with Parkinson’s disease, I recommend carrying the Parkinson’s Passport when traveling. Created by the European Parkinson’s Disease Association (EPDA), it helps communicate essential medical needs in emergencies—offering reassurance and support far from home.
🔗 Parkinson’s Passport – EPDA
Because the right knowledge, at the right time, can change lives.
Poststraße 3, 79098 Freiburg
Telephone: 0761 8982 3074
Telephone inquiries are welcome at any time between 8:00 AM and 12:00 PM.
If we are unable to answer your call immediately, we will of course call you back.
E-Mail: info@jarcadian.de
